1034976-50-5

Basic information

• Product Name: 4-(4-Carboxy-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-(4-Carboxy-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 1034976-50-5
• Molecular Formula: C₁₄H₂₁N₃O₄
• Molecular Weight: 295
• Mol File: 1034976-50-5.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-Carboxy-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Carboxy-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester(1034976-50-5)
• EPA Substance Registry System: 4-(4-Carboxy-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester(1034976-50-5)

Safety Data

• Hazardous Substances Data: 1034976-50-5(Hazardous Substances Data)

Usage

Description

4-(4-Carboxy-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester is a complex organic molecule that features a piperidine ring with a pyrazole group attached to it. This molecule also incorporates a carboxylic acid group and is capped with a tert-butyl ester. It is frequently utilized in pharmaceutical research and drug development, particularly for the creation of potential therapeutic agents addressing a range of medical conditions. The molecule's structure allows for modifications and optimizations to target specific biological activities, positioning it as a promising candidate for new drug development. The tert-butyl ester group contributes to the molecule's stability and offers protection, facilitating controlled release or activation within biological systems.

Uses

Used in Pharmaceutical Research and Drug Development:
4-(4-Carboxy-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester serves as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of drugs with specific biological activities tailored to treat different medical conditions.
Used in the Development of Therapeutic Agents:
In the medical industry, 4-(4-Carboxy-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester is used as a building block for the creation of potential therapeutic agents. Its adaptability in molecular design makes it suitable for addressing a wide array of health issues.
Used for Controlled Release or Activation:
The tert-butyl ester group in 4-(4-Carboxy-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester provides stability and protection to the molecule. This feature is utilized in applications requiring controlled release or activation of the drug in biological systems, ensuring optimal therapeutic effects and minimizing side effects.

Upstream product

• 118811-07-7 tert-butyl 4-(tosyloxy)piperidin-1-carboxylate 
• 37622-90-5 4-ethoxycarbonylpyrazole 
• 141699-59-4 1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 782493-64-5 4-(4-ethoxycarbonylpyrazol-1-yl)piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1108745-84-1 C₂₈H₃₀F₂N₆O₃ 

Relevant articles and documents

6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL-(5-MEMBERED HETEROARYL) CARBOXAMIDES AND PREPARATION AND USE THEREOF

Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

NAPHTHYRIDINES AS INHIBITORS OF HPK1

Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

MONOCYCLIC PYRIDINE DERIVATIVE

The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or —CH2—; E represents a nitrogen-containing non-aromatic heterocycle; R1 represents an alkoxy group or the like; R2 represents a hydrogen atom or the like; and R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.